Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
Int J Infect Dis
; 143: 107012, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38521448
ABSTRACT
OBJECTIVES:
This study aims to estimate the causal effects of oral antivirals and vaccinations in the prevention of all-cause mortality and progression to severe COVID-19 in an integrative setting with both antivirals and vaccinations considered as interventions.METHODS:
We identified hospitalized adult patients (i.e. aged 18 or above) in Hong Kong with confirmed SARS-CoV-2 infection between March 16, 2022, and December 31, 2022. An inverse probability-weighted (IPW) Andersen-Gill model with time-dependent predictors was used to address immortal time bias and produce causal estimates for the protection effects of oral antivirals and vaccinations against severe COVID-19.RESULTS:
Given prescription is made within 5 days of confirmed infection, nirmatrelvir-ritonavir is more effective in providing protection against all-cause mortality and development into severe COVID-19 than molnupiravir. There was no significant difference between CoronaVac and Comirnaty in the effectiveness of reducing all-cause mortality and progression to severe COVID-19.CONCLUSIONS:
The use of oral antivirals and vaccinations causes lower risks of all-cause mortality and progression to severe COVID-19 for hospitalized SARS-CoV-2 patients.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
País/Región como asunto:
Asia
Idioma:
En
Revista:
Int J Infect Dis
/
Int. j. infect. dis
/
International journal of infectious diseases
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2024
Tipo del documento:
Article